Revenue was absent throughout the period, and quarterly operating losses widened from -$11.9M in 2024Q1 to -$23.3M in 2026Q2 as R&D expense grew to $17.0M, leaving no margin base to evaluate.
Protara Therapeutics, Inc. (TARA) annual income statement — 14-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.95M | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | -100% | - | - | - |
| Cost of Goods Sold | 90K | 362K | 0 | 341K | 0 | 0 | 196K | 16K | 115K | 148K | 123K | 57K | 0 | 27K | 57K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -90K | -362K | 0 | -341K | 0 | 0 | -196K | -16K | -115K | -148K | -123K | -57K | 2.95M | -27K | -57K |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - |
| Gross Profit Growth % | - | - | 100% | - | - | 100% | -1125% | 86.09% | 22.3% | -20.33% | -115.79% | -101.93% | 11018.52% | 52.63% | - |
| Operating Expenses | 85.1M | 64.19M | 49.15M | 43.27M | 67.06M | 47.49M | 34.25M | 15.25M | 26.08M | 30.21M | 28.58M | 20.81M | 10.53M | 7.09M | 7.94M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 357.12% | - | - |
| Selling, General & Admin | 24.74M | 21.92M | 17.45M | 18.62M | 20.74M | 26.4M | 22.36M | 8.82M | 10.57M | 8.53M | 9.71M | 8.43M | 4.1M | 3.1M | 2.03M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 138.94% | - | - |
| Research & Development | 60.36M | 42.63M | 31.7M | 24.79M | 16.81M | 21.09M | 11.88M | 6.44M | 15.51M | 21.69M | 18.87M | 12.38M | 6.43M | 3.99M | 5.91M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 218.18% | - | - |
| Other Operating Expenses | 0 | -362K | 0 | -137K | 29.52M | 0 | 0 | 0 | 207K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -85.19M | -64.55M | -49.15M | -43.61M | -67.06M | -47.49M | -34.44M | -15.25M | -26.08M | -30.36M | -28.7M | -20.87M | -7.58M | -7.12M | -8M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | -257.12% | - | - |
| Operating Income Growth % | - | -31.32% | -12.7% | 34.97% | -41.22% | -37.87% | -125.8% | 41.51% | 14.1% | -5.77% | -37.54% | -175.33% | -6.43% | 10.93% | - |
| EBITDA | -84.93M | -64.19M | -48.82M | -43.27M | -66.81M | -47.37M | -34.25M | -15.24M | -25.96M | -30.21M | -28.58M | -20.81M | -7.55M | -7.09M | -7.94M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - | -256.11% | - | - |
| EBITDA Growth % | -42.91% | -31.47% | -12.83% | 35.24% | -41.04% | -38.32% | -124.75% | 41.31% | 14.06% | -5.71% | -37.33% | -175.67% | -6.41% | 10.63% | - |
| D&A (Non-Cash Add-back) | 255K | 362K | 332K | 341K | 248K | 117K | 196K | 16K | 115K | 148K | 123K | 57K | 30K | 27K | 57K |
| EBIT | -56.76M | -57.44M | -44.6M | -40.42M | -64.81M | -45.52M | -33.98M | -7.83M | -20.73M | -29.96M | -28.53M | -21.38M | -2.48M | -7.05M | -7.97M |
| Net Interest Income | 3.34M | 6.33M | 4.13M | 2.73M | -27K | -1.5M | 432K | 0 | 0 | 0 | 0 | 0 | 0 | -857K | 20K |
| Interest Income | 3.34M | 6.33M | 4.13M | 2.73M | 1.11M | 237K | 466K | 0 | 0 | 0 | 0 | 0 | 0 | 4K | 20K |
| Interest Expense | 1.47M | 0 | 0 | 0 | 1.14M | 1.74M | 34K | 0 | 0 | 259K | 193K | 144K | 857K | 861K | 0 |
| Other Income/Expense | 6.74M | 7.11M | 4.56M | 3.19M | 1.11M | 237K | 466K | 0 | 643K | 398K | 179K | -507K | 4.24M | -790K | 26K |
| Pretax Income | -78.44M | -57.44M | -44.6M | -40.42M | -65.95M | -47.25M | -33.98M | -14.99M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - | -113.37% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -262K | 5.35M | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 1.75% | -21.04% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -78.44M | -57.44M | -44.6M | -40.42M | -65.95M | -47.25M | -33.98M | -14.99M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | -113.37% | - | - |
| Net Income Growth % | -48.29% | -28.8% | -10.33% | 38.71% | -39.57% | -39.07% | -126.64% | 41.06% | 15.11% | -5.04% | -33.44% | -539.65% | 57.76% | 0.73% | - |
| Net Income (Continuing) | -78.44M | -57.44M | -44.6M | -40.42M | -65.95M | -47.25M | -33.98M | -7.83M | -20.73M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.25 | -1.34 | -2.17 | -3.57 | -5.86 | -4.20 | -4.70 | -3.63 | -9.93 | -69.38 | -68.90 | -51.94 | -10.24 | -37.43 | -37.62 |
| EPS Growth % | 2.1% | 38.25% | 39.22% | 39.08% | -39.52% | 10.64% | -29.48% | 63.44% | 85.69% | -0.7% | -32.65% | -407.23% | 72.64% | 0.51% | - |
| EPS (Basic) | - | -1.34 | -2.17 | -3.57 | -5.86 | -4.20 | -4.70 | -3.63 | -9.93 | -69.38 | -68.90 | -51.94 | -10.24 | -37.43 | -37.62 |
| Diluted Shares Outstanding | 62.85M | 42.84M | 20.59M | 11.33M | 11.26M | 11.23M | 7.23M | 4.06M | 2.56M | 431.86K | 414.04K | 411.6K | 326.21K | 374.85K | 374.85K |
| Basic Shares Outstanding | 62.85M | 42.84M | 20.59M | 11.33M | 11.26M | 11.23M | 7.23M | 4.06M | 2.56M | 431.86K | 414.04K | 411.6K | 326.21K | 374.85K | 374.85K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying TARA stock.
For fiscal year 2025, Protara Therapeutics, Inc. (TARA) reported total revenue of $0.0M.
Protara Therapeutics, Inc. (TARA) reported a net loss of $57.4M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Persistent R&D-driven operating losses
Metrics are mathematically derived from official filings.
Revenue Absent, Losses Widening Gradually
Based on reported figures, TARA recorded no meaningful revenue across the ten quarters shown, with operating losses moving from -$11.9M in 2024Q1 to -$23.3M in 2026Q2, a roughly doubling of quarterly operating deficit.
The absence of revenue means growth cannot be assessed in conventional terms, and the income statement instead reflects a pre-commercial cost base. The widening deficit appears driven primarily by rising R&D spend, which moved from $7.7M to $17.0M over the period, suggesting the company is scaling clinical development activity. Investors should monitor whether this expansion translates into a value-creating pipeline or simply extends the runway requirement.
R&D Dominates a Rising Expense Base
As reported in financial statements, TARA's R&D expense rose from $7.7M in 2024Q1 to $17.0M in 2026Q2, accounting for the large majority of total operating expenses in each quarter.
R&D represents roughly three-quarters of combined R&D and SG&A in recent periods, indicating that cash consumption is concentrated in development rather than overhead. SG&A has grown more modestly, from $4.1M to $6.4M, which suggests comparatively disciplined general and administrative spending. The cost mix points to a clinical-stage model whose burn rate is closely tied to trial activity timing.
Net Loss Tracks Operations, Modest Non-Operating Offset
Based on EDBL's reported figures, TARA's net loss of -$21.7M in 2026Q2 was slightly smaller than its operating loss of -$23.3M, indicating a modest non-operating income contribution.
The gap between operating and net loss is small and does not appear to be materially distorting reported earnings. Stock-based compensation of roughly $1.0M to $1.4M per quarter is modest relative to the loss magnitude, so it does not appear to be a dominant driver of the reported deficit. Per-share losses have been influenced by share count changes, and the EPS trend should be read alongside dilution considerations.
Persistent Losses Raise Funding Dependence Questions
According to recent SEC filings, TARA's operating losses have exceeded $10M in every quarter shown, implying that continued development may depend on external capital access that the supplied data does not fully describe.
Given the absence of revenue and a deficit that has grown with R&D intensity, the income statement alone cannot confirm the sufficiency of existing resources. The data does not disclose cash balances or financing arrangements, so any conclusion about runway would be inference rather than fact. Investors should monitor future financing announcements and any shift in R&D spending pace as signals of capital requirements.